Skip to main content

Table 1 Baseline characteristics of patients with stage III NPC (N = 272)

From: Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up

Variables

IMRT alone (N = 82)

CCRT (N = 190)

P

Sex

  

0.020

Male

72 (87.8%)

143 (75.3%)

 

Female

10 (12.2%)

47 (24.7%)

 

Age (year)

  

0.303

≤ 43

38 (46.3%)

101 (53.2%)

 

> 43

44 (53.7%)

89 (46.8%)

 

Smoking

  

0.070

Yes

43 (52.4%)

113 (59.5%)

 

No

39 (47.6%)

77 (40.5%)

 

Alcohol

  

0.368

Yes

19 (23.2%)

155 (81.6%)

 

No

63 (76.8%)

35 (18.4%)

 

T classification

  

0.146

T1-2

12 (26.8%)

36 (18.9%)

 

T3

60 (73.2%)

154 (81.1%)

 

N classification

  

0.970

N0-1

49 (59.8%)

114 (60.0%)

 

N2

33 (40.2%)

76 (40.0%)

 

EBV DNA

  

0.398

< 2000

25 (30.5%)

68 (35.8%)

 

≥ 2000

57 (69.5%)

122 (64.2%)

 
  1. NPC, nasopharyngeal carcinoma; IMRT, intensity-modulated radiation therapy; CCRT, concurrent chemoradiotherapy; EBV, Epstein–Barr virus